C reactive protein (crp)

The concentrations of CEA and CYFRA211 in the plasma were assessed using electrochemiluminescence immunoassay (ECLIA) kits (Roche, Germany) on a Roche E170 fully automatic electrochemistry luminescence immunity analyzer (Roche, German). The levels of SCCA in the plasma were detected using an ARCHITECT I2000SR immune analyze system (Abbott, America). Each test included a standard control (CV < 5%).
The plasma biochemical indices including TG, CHO, HDL-C, LDL-C(WAKO, Japan), ApoA1, Apo-B(Maccura,China) and inflammatory biomarker CRP (WAKO, Japan) were measured on an automatic biochemical analyzer (LABOSPECT 008; Hitachi HighTechnologies Corporation, Japan).
The plasma hemostasis indices including PT, APTT, FBG, TT, DD (Siemens, Germany) and FDP (BIOLINKS CO., LTD, Japan) were measured on an automatic coagulation analyzer (SYSMEX CS-5100 Hemostasis System, Japan). PT% and INR were calculated according to the formula recommended by the manufacture’s instruction.

Plasma levels of total cholesterol, HDL-C, LDL-C, triglycerides, glucose, LDH, and hepatic transaminases (ALT and AST) were determined by the hospital’s laboratory. The plasma parameters presented in Table 1 were measured using the following commercially available kits: APOA-I and APOE (Mabtech, Nacka Strand, Sweden), PON1 and MPO (R&D Systems, Minneapolis, MN, USA), MPO activity (Cayman Chemical, Ann Arbor, MI, USA), CP (Abnova, Taipei, Taiwan), and CRP (Wako Chemicals GmbH, Neuss, Germany). All assays were performed according to the manufacturer’s instructions. PON1 activity was measured using an adapted method in the serum of the patients [43 (link)].